

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

NationalInvestments

National Investments Fund Limited 國盛投資基金有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1227)

VOLUNTARY ANNOUNCEMENT: APPOINTMENT OF DIRECTORS OF MEDISUN

This announcement is made by National Investments Fund Limited (“**Company**”) on a voluntary basis.

The board (“**Board**”) of directors (each, a “**Director**”) of the Company is pleased to announce that it has been informed by Medisun Holdings Limited (“**Medisun**”) that Dr. Robert Charles Gallo (“**Dr. Gallo**”) and Mr. Terry L. Lierman (“**Mr. Lierman**”) have been appointed as directors of Medisun.

Dr. Gallo is an American biomedical researcher. He is best known for his role in the discovery of the human immunodeficiency virus (HIV) as the infectious agent responsible for acquired immune deficiency syndrome (AIDS) and in the development of the HIV blood test, and he has been a major contributor to subsequent HIV research. In 1984, Dr. Gallo and his collaborators published that a retrovirus they had isolated, called HTLV-III in the belief that the virus was related to the leukemia viruses of Gallo's earlier work, was the cause of AIDS. In 1986, Dr. Gallo and his collaborators discovered human herpesvirus 6 (HHV-6), later found to cause Roseola infantum, an infantile disease. In 1982, 1984, 1985 and 1988, Dr. Gallo received the prestigious Lasker Award, the Charles S. Mott Prize, the Dickson Prize and the Japan Prize respectively. Dr. Gallo is the director and co-founder of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine, and co-founder and scientific director of the Global Virus Network (GVN). Dr. Gallo has been a researcher at the National Cancer Institute, where he worked for 30 years, mainly as head of the Laboratory of Tumor Cell Biology.

Mr. Lierman is the founder of Summit Global Ventures, and the executive officer of Health Ventures, LLC. Mr. Lierman worked with the U.S. Senate Committee on Appropriations, where he served as the staff director of the Labor Health and Human Services (HHS) Appropriations Subcommittee as well as the full committee. Mr. Lierman is also the founder of Research America and the NIH (U.S. National Institutes of Health)/the FDA (U.S. Food and Drug Administration) Council. He served as the Chief of Staff to the House of Representatives Majority Leader and Democratic Whip Congressman Steny H. Hoyer. He began his career in the health field at the U.S. National Institutes of Health (NIH) in 1971. In the past 40 years, he has been involved in venture capital, business development and management. He has also served as the chairman of the Maryland Democratic Party.

Medisun is an associated company of the Company incorporated in Hong Kong with limited liability. The Company currently holds approximately 30% shareholding in Medisun.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
National Investments Fund Limited
Wong Danny F.
Chairman and executive Director

Hong Kong, 20 February 2017

As at the date of this announcement, the Board of the Company comprises three executive Directors, namely Mr. Wong Danny F. (Chairman), Mr. Wu Tse Wai, Frederick, Mr. Fong Chi Wah; two non-executive Directors, namely Mr. Gao Chengming and Mr. Lau Chi Lung, Johnny; and three independent non-executive Directors, namely Mr. Char Shik Ngor, Stephen, Mr. Liu Jin and Mr. Law Tze Lun.